R&D

CVDHKG: 3696

Insilico Medicine Nominates ISM0900, AI‑Designed Oral Lp(a) Inhibitor, as 9th Preclinical Candidate of 2026

Insilico Medicine (HKG: 3696) announced the nomination of ISM0900 — a potent, highly selective, oral small‑molecule inhibitor powered by AI — as a Preclinical Candidate (PCC). Targeting lipoprotein(a), or Lp(a),…

Insilico Medicine Nominates AI-Discovered ISM9077 as 32nd Preclinical Candidate Targeting Ophthalmic and Inflammatory Diseases

Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Gene therapyGenomics / NGS

China’s CNIPA Upholds Patent for Nobel-Winning CRISPR/Cas9 Gene Editing Technology

Tianjin University Team Develops Self-Sustaining Na-O2 Battery for Implantable Devices

AI

CAIR Launches CARES Copilot 1.0: A Revolutionary AI Chatbot for Medical Diagnosis and Treatment

CancerNHC (NHFPC)

China Reports Over 4.8 Million New Cancer Cases in 2022 Amid Rising Incidence and Mortality Rates

Show More